SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Delayed Nasdaq  -  04:00 2022-08-10 pm EDT
42.84 USD   +1.66%
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Rating
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
38.34(c) 41.95(c) 43.02(c) 42.14(c) 42.84(c) Last
611 108 1 060 896 859 397 516 544 315 218 Volume
+6.44% +9.42% +2.55% -2.05% +1.66% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 6,96 M - -
Net income 2022 -519 M - -
Net cash position 2022 1 121 M - -
P/E ratio 2022 -4,93x
Yield 2022 -
Sales 2023 123 M - -
Net income 2023 -462 M - -
Net cash position 2023 915 M - -
P/E ratio 2023 -5,79x
Yield 2023 -
Capitalization 2 530 M 2 530 M -
EV / Sales 2022 202x
EV / Sales 2023 13,2x
Nbr of Employees 471
Free-Float 87,5%
More Financials
Company
Sage Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing medicines with debilitating disorders of the brain. The Company's product, ZULRESSO (brexanolone) CIV injection, is for the treatment of postpartum depression (PPD) in adults. It has a portfolio of other product candidates with a focus on modulating two central nervous system (CNS) receptor systems, GABA and NMDA. 
Sector
Biotechnology & Medical Research
Calendar
08/10 | 10:00amPresentation
More about the company
Ratings of Sage Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about SAGE THERAPEUTICS, INC.
08/03Goldman Sachs Adjusts Sage Therapeutics' Price Target to $73 From $74, Keeps Buy Rating
MT
08/03Citigroup Trims Price Target on Sage Therapeutics to $40 From $41, Maintains Neutral Ra..
MT
08/03Wedbush Trims Price Target on Sage Therapeutics to $52 From $54, Keeps Outperform Ratin..
MT
08/02TRANSCRIPT : Sage Therapeutics, Inc., Q2 2022 Earnings Call, Aug 02, 2022
CI
08/02Sage Therapeutics Widens Q2 Net Loss as Revenue Declines
MT
08/02SAGE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
08/02Sage Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months ..
CI
08/02SAGE THERAPEUTICS : Announces Second Quarter 2022 Financial Results and Highlights Pipelin..
PU
08/02Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeli..
BU
08/01Sage Therapeutics to Present at Upcoming August Investor Conferences
BU
07/19Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2,..
BU
07/14SAGE THERAPEUTICS : IF YOU DO NOT OBJECT TO THE PROPOSED SETTLEMENT, OR THE AGREED-TO ATTO..
PU
07/14SAGE THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/11SVB Securities Adjusts Sage Therapeutics' Price Target to $40 from $50, Keeps Market Pe..
MT
07/01Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcar..
MT
More news
News in other languages on SAGE THERAPEUTICS, INC.
08/02Sage Therapeutics creuse sa perte nette au 2e trimestre et voit ses revenus diminuer
08/02Sage Therapeutics, Inc. annonce ses résultats financiers pour le deuxième trimestre et ..
06/13Sage Therapeutics, Inc. fournit une mise à jour sur la demande de nouveau médicament po..
06/01Le médicament de Sage-Biogen améliore les symptômes dans une étude sur la dépression po..
06/01USA-Les valeurs à suivre à Wall Street (actualisé)
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 42,84 $
Average target price 57,81 $
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.0.71%2 530
GILEAD SCIENCES, INC.-13.04%77 767
VERTEX PHARMACEUTICALS34.69%76 638
REGENERON PHARMACEUTICALS, INC.1.58%66 513
WUXI APPTEC CO., LTD.-23.13%40 267
BIONTECH SE-37.58%38 205